首页 > 最新文献

Korean Journal of Urology最新文献

英文 中文
Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists. 前列腺癌的多参数磁共振成像:泌尿科医生的回顾和更新。
Pub Date : 2015-07-01 Epub Date: 2015-06-30 DOI: 10.4111/kju.2015.56.7.487
Sangjun Yoo, Jeong Kon Kim, In Gab Jeong

Recently, imaging of prostate cancer has greatly advanced since the introduction of multiparametric magnetic resonance imaging (mpMRI). mpMRI consists of T2-weighted sequences combined with several functional sequences including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and/or magnetic resonance spectroscopy imaging. Interest has been growing in mpMRI because no single MRI sequence adequately detects and characterizes prostate cancer. During the last decade, the role of mpMRI has been expanded in prostate cancer detection, staging, and targeting or guiding prostate biopsy. Recently, mpMRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mpMRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. In this regard, some urologic clinical practice guidelines recommended the use of mpMRI in the diagnosis and management of prostate cancer. Because mpMRI is the evolving reference standard imaging modality for prostate cancer, urologists should acquire cutting-edge knowledge about mpMRI. In this article, we review the literature on the use of mpMRI in urologic practice and provide a brief description of techniques. More specifically, we state the role of mpMRI in prostate biopsy, active surveillance, high-risk prostate cancer, and detection of recurrence after radical prostatectomy.

近年来,自多参数磁共振成像(mpMRI)的引入以来,前列腺癌的影像学有了很大的进展。mpMRI由t2加权序列和几个功能序列组成,包括扩散加权成像、动态对比增强成像和/或磁共振波谱成像。由于没有单一的MRI序列能够充分地检测和表征前列腺癌,人们对mpMRI越来越感兴趣。在过去的十年中,mpMRI在前列腺癌的检测、分期、靶向或指导前列腺活检方面的作用已经扩大。最近,mpMRI已被用于评估前列腺癌的侵袭性,并在主动监测之前和期间确定肿瘤的前部。此外,最近的研究报道,mpMRI是一种可靠的成像方式,用于检测根治性前列腺切除术或外束放射治疗后的局部复发。在这方面,一些泌尿外科临床实践指南推荐使用mpMRI诊断和治疗前列腺癌。由于mpMRI是不断发展的前列腺癌参考标准成像方式,泌尿科医生应该掌握有关mpMRI的前沿知识。在本文中,我们回顾了在泌尿外科实践中使用mpMRI的文献,并提供了技术的简要描述。更具体地说,我们阐述了mpMRI在前列腺活检、主动监测、高风险前列腺癌和根治性前列腺切除术后复发检测中的作用。
{"title":"Multiparametric magnetic resonance imaging for prostate cancer: A review and update for urologists.","authors":"Sangjun Yoo,&nbsp;Jeong Kon Kim,&nbsp;In Gab Jeong","doi":"10.4111/kju.2015.56.7.487","DOIUrl":"https://doi.org/10.4111/kju.2015.56.7.487","url":null,"abstract":"<p><p>Recently, imaging of prostate cancer has greatly advanced since the introduction of multiparametric magnetic resonance imaging (mpMRI). mpMRI consists of T2-weighted sequences combined with several functional sequences including diffusion-weighted imaging, dynamic contrast-enhanced imaging, and/or magnetic resonance spectroscopy imaging. Interest has been growing in mpMRI because no single MRI sequence adequately detects and characterizes prostate cancer. During the last decade, the role of mpMRI has been expanded in prostate cancer detection, staging, and targeting or guiding prostate biopsy. Recently, mpMRI has been used to assess prostate cancer aggressiveness and to identify anteriorly located tumors before and during active surveillance. Moreover, recent studies have reported that mpMRI is a reliable imaging modality for detecting local recurrence after radical prostatectomy or external beam radiation therapy. In this regard, some urologic clinical practice guidelines recommended the use of mpMRI in the diagnosis and management of prostate cancer. Because mpMRI is the evolving reference standard imaging modality for prostate cancer, urologists should acquire cutting-edge knowledge about mpMRI. In this article, we review the literature on the use of mpMRI in urologic practice and provide a brief description of techniques. More specifically, we state the role of mpMRI in prostate biopsy, active surveillance, high-risk prostate cancer, and detection of recurrence after radical prostatectomy. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 7","pages":"487-97"},"PeriodicalIF":0.0,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.7.487","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34008005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 38
Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction. 充气阴茎假体治疗勃起功能障碍的长期生存率及患者满意度。
Pub Date : 2015-06-01 Epub Date: 2015-06-02 DOI: 10.4111/kju.2015.56.6.461
Yoon Seob Ji, Young Hwii Ko, Phil Hyun Song, Ki Hak Moon

Purpose: We investigated the long-term survival and patient satisfaction with an inflatable penile prosthesis as a treatment for refractory erectile dysfunction (ED).

Materials and methods: Between July 1997 and September 2014, a total of 74 patients underwent implantation of an inflatable penile prosthesis. The present mechanical status of the prosthesis was ascertained by telephone interview and review of medical records, and related clinical factors were analyzed by using Cox proportional hazard regression model. To investigate current status and satisfaction with the devices, novel questionnaires consisting of eight items were administered.

Results: The mean (±standard deviation) age and follow-up period were 57.0±12.2 years and 105.5±64.0 months, respectively. Sixteen patients (21.6%) experienced a mechanical failure and 4 patients (5.4%) experienced a nonmechanical failure at a median follow-up of 98.0 months. Mechanical and overall survival rates of the inflatable penile prosthesis at 5, 10, and 15 years were 93.3%, 76.5%, and 64.8% and 89.1%, 71.4%, and 60.5%, respectively, without a statistically significant correlation with host factors including age, cause of ED, and presence of obesity, hypertension, and diabetes mellitus. Overall, 53 patients (71.6%) completed the questionnaires. The overall patient satisfaction rate was 86.8%, and 83.0% of the patients replied that they intended to repeat the same procedure. Among the 8 items asked, satisfaction with the rigidity of the device received the highest score (90.6%). In contrast, only 60.4% of subjects experienced orgasm.

Conclusions: The results of our study suggest that excellent long-term reliability and high patient satisfaction rates make the implantation of an inflatable penile prosthesis a recommendable surgical treatment for refractory ED.

目的:研究充气阴茎假体治疗难治性勃起功能障碍(ED)的长期生存率和患者满意度。材料与方法:1997年7月至2014年9月,共74例患者行充气阴茎假体植入术。通过电话访谈和查阅病历了解假体目前的力学状况,并采用Cox比例风险回归模型分析相关临床因素。为了调查设备的现状和满意度,采用了包含8个项目的新颖问卷。结果:患者平均(±标准差)年龄为57.0±12.2岁,随访时间为105.5±64.0个月。在98.0个月的中位随访中,16例患者(21.6%)出现机械故障,4例患者(5.4%)出现非机械故障。充气阴茎假体5年、10年、15年的机械生存率、总生存率分别为93.3%、76.5%、64.8%、89.1%、71.4%、60.5%,与宿主年龄、ED病因、有无肥胖、高血压、糖尿病等因素无统计学意义相关。总共53例患者(71.6%)完成了问卷调查。总体患者满意率为86.8%,83.0%的患者回答有重复手术意向。在被问及的8个项目中,对器械刚性的满意度得分最高(90.6%)。相比之下,只有60.4%的受试者体验到了性高潮。结论:我们的研究结果表明,充气阴茎假体植入具有良好的长期可靠性和较高的患者满意度,是难治性ED的一种值得推荐的手术治疗方法。
{"title":"Long-term survival and patient satisfaction with inflatable penile prosthesis for the treatment of erectile dysfunction.","authors":"Yoon Seob Ji,&nbsp;Young Hwii Ko,&nbsp;Phil Hyun Song,&nbsp;Ki Hak Moon","doi":"10.4111/kju.2015.56.6.461","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.461","url":null,"abstract":"<p><strong>Purpose: </strong>We investigated the long-term survival and patient satisfaction with an inflatable penile prosthesis as a treatment for refractory erectile dysfunction (ED).</p><p><strong>Materials and methods: </strong>Between July 1997 and September 2014, a total of 74 patients underwent implantation of an inflatable penile prosthesis. The present mechanical status of the prosthesis was ascertained by telephone interview and review of medical records, and related clinical factors were analyzed by using Cox proportional hazard regression model. To investigate current status and satisfaction with the devices, novel questionnaires consisting of eight items were administered.</p><p><strong>Results: </strong>The mean (±standard deviation) age and follow-up period were 57.0±12.2 years and 105.5±64.0 months, respectively. Sixteen patients (21.6%) experienced a mechanical failure and 4 patients (5.4%) experienced a nonmechanical failure at a median follow-up of 98.0 months. Mechanical and overall survival rates of the inflatable penile prosthesis at 5, 10, and 15 years were 93.3%, 76.5%, and 64.8% and 89.1%, 71.4%, and 60.5%, respectively, without a statistically significant correlation with host factors including age, cause of ED, and presence of obesity, hypertension, and diabetes mellitus. Overall, 53 patients (71.6%) completed the questionnaires. The overall patient satisfaction rate was 86.8%, and 83.0% of the patients replied that they intended to repeat the same procedure. Among the 8 items asked, satisfaction with the rigidity of the device received the highest score (90.6%). In contrast, only 60.4% of subjects experienced orgasm.</p><p><strong>Conclusions: </strong>The results of our study suggest that excellent long-term reliability and high patient satisfaction rates make the implantation of an inflatable penile prosthesis a recommendable surgical treatment for refractory ED.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"461-5"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.461","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 43
Analysis of factors affecting spontaneous expulsion of ureteral stones that may predict unfavorable outcomes during watchful waiting periods: What is the influence of diabetes mellitus on the ureter? 观察等待期输尿管结石自发排出的影响因素分析:糖尿病对输尿管的影响是什么?
Pub Date : 2015-06-01 Epub Date: 2015-05-27 DOI: 10.4111/kju.2015.56.6.455
Taesoo Choi, Koo Han Yoo, Seung-Kwon Choi, Dong Soo Kim, Dong-Gi Lee, Gyeong Eun Min, Seung Hyun Jeon, Hyung-Lae Lee, In-Kyung Jeong

Purpose: The aim of our study was to evaluate the association of several factors with spontaneous stone expulsion, including ureteral stone characteristics (size, location, hydronephrosis, perinephric stranding), types of medications prescribed (α-blocker, low-dose steroid), and other possible demographic and health-history factors (gender, age, serum creatinine, underlying diabetes mellitus [DM], and hypertension).

Materials and methods: A total of 366 patients with ureteral stones were enrolled. All patients underwent watchful waiting without any invasive procedures. Initial diagnoses of ureteral stones were confirmed by computed tomography scans, which were taken at approximately 1-month intervals to check for stone expulsion. Univariate and multivariate analyses were conducted to identify significant factors that contributed to stone expulsion.

Results: Among 366 patients, 335 patients (91.5%) experienced spontaneous stone passage during a mean follow-up period of 2.95±2.62 weeks. The patients were divided into two groups depending on the success of spontaneous stone passage. Univariate analyses revealed that stone location (p=0.003), stone size (p=0.021), and underlying DM (p<0.001) were significant predictors of stone passage. Multivariate analyses confirmed that stone size (p=0.010), stone location (p=0.008), and underlying DM (p=0.003) were independent predictive factors affecting stone passage.

Conclusions: Stone size, location, and underlying DM were confirmed to be significant predictive factors for spontaneous passage of ureteral stones. Urologists should consider active procedures, such as shock wave lithotripsy or ureteroscopy, rather than conservative management in patients presenting with proximally located stones, large ureteral stones, or underlying DM.

目的:本研究的目的是评估几个因素与自发性结石排出的关系,包括输尿管结石特征(大小、位置、肾积水、肾周搁浅)、处方药物类型(α-阻滞剂、低剂量类固醇)以及其他可能的人口统计学和健康历史因素(性别、年龄、血清肌酐、潜在糖尿病[DM]和高血压)。材料与方法:共纳入366例输尿管结石患者。所有患者均行观察等待,无任何侵入性手术。输尿管结石的初步诊断是通过计算机断层扫描确认的,大约每隔1个月进行一次,检查结石排出情况。进行了单因素和多因素分析,以确定导致结石排出的重要因素。结果:366例患者中,335例(91.5%)患者在平均随访时间(2.95±2.62周)内发生自发性结石结石。根据结石自行排出的成功程度将患者分为两组。单因素分析显示,结石位置(p=0.003)、结石大小(p=0.021)和潜在糖尿病(p)是输尿管结石自发通过的重要预测因素。结论:结石大小、位置和潜在糖尿病是输尿管结石自发通过的重要预测因素。对于近端结石、大输尿管结石或潜在糖尿病患者,泌尿科医生应考虑积极治疗,如冲击波碎石或输尿管镜检查,而不是保守治疗。
{"title":"Analysis of factors affecting spontaneous expulsion of ureteral stones that may predict unfavorable outcomes during watchful waiting periods: What is the influence of diabetes mellitus on the ureter?","authors":"Taesoo Choi,&nbsp;Koo Han Yoo,&nbsp;Seung-Kwon Choi,&nbsp;Dong Soo Kim,&nbsp;Dong-Gi Lee,&nbsp;Gyeong Eun Min,&nbsp;Seung Hyun Jeon,&nbsp;Hyung-Lae Lee,&nbsp;In-Kyung Jeong","doi":"10.4111/kju.2015.56.6.455","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.455","url":null,"abstract":"<p><strong>Purpose: </strong>The aim of our study was to evaluate the association of several factors with spontaneous stone expulsion, including ureteral stone characteristics (size, location, hydronephrosis, perinephric stranding), types of medications prescribed (α-blocker, low-dose steroid), and other possible demographic and health-history factors (gender, age, serum creatinine, underlying diabetes mellitus [DM], and hypertension).</p><p><strong>Materials and methods: </strong>A total of 366 patients with ureteral stones were enrolled. All patients underwent watchful waiting without any invasive procedures. Initial diagnoses of ureteral stones were confirmed by computed tomography scans, which were taken at approximately 1-month intervals to check for stone expulsion. Univariate and multivariate analyses were conducted to identify significant factors that contributed to stone expulsion.</p><p><strong>Results: </strong>Among 366 patients, 335 patients (91.5%) experienced spontaneous stone passage during a mean follow-up period of 2.95±2.62 weeks. The patients were divided into two groups depending on the success of spontaneous stone passage. Univariate analyses revealed that stone location (p=0.003), stone size (p=0.021), and underlying DM (p<0.001) were significant predictors of stone passage. Multivariate analyses confirmed that stone size (p=0.010), stone location (p=0.008), and underlying DM (p=0.003) were independent predictive factors affecting stone passage.</p><p><strong>Conclusions: </strong>Stone size, location, and underlying DM were confirmed to be significant predictive factors for spontaneous passage of ureteral stones. Urologists should consider active procedures, such as shock wave lithotripsy or ureteroscopy, rather than conservative management in patients presenting with proximally located stones, large ureteral stones, or underlying DM.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"455-60"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.455","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Current status of stem cell therapy in urology. 泌尿外科干细胞治疗的现状。
Pub Date : 2015-06-01 DOI: 10.4111/kju.2015.56.6.409
Jae Heon Kim, Yun Seob Song
Stem cells have the ability to propagate through self renewal and generate mature cells of multiple lineages through differentiation [1,2]. Explorations of the potential value of stem cell therapy in urology have included studies of bladder dysfunction, erectile dysfunction (ED), stress urinary incontinence (SUI), and prostate and bladder cancer. Only a few pilot human translational studies study of stress incontinence and diabetes induced ED have been reported. Recently, Alwaal et al. [3] introduced the current status of stem cell treatment in benign urological diseases including ED, Peyronie disease, infertility and SUI. The prowess of stem cell therapy has been indicated in bladder dysfunction models including bladder outlet obstruction, chronic ischemia, diabetes, cryo-injury, pelvic nerve injury, and spinal cord injury (SCI). Except for cryo-injury and pelvic nerve injury, models have demonstrated overactive urodynamics, indicative of improved inter-contraction interval and maximal voiding pressure [1,2]. Underactivity models including cryo-injury and pelvic nerve injury models have demonstrated improvements of intravesical pressure. Marked smooth muscle differentiation has been reported in three studies. Concerning SCI-induced bladder dysfunction, a meta-analysis affirmed that stem cell-based cell therapyproduces partial bladder recovery including improvement of voiding pressure, inter-contraction interval, and residual urine [4]. For ED, stem cell injection into the corpus cavernosum or periprostatic implantation improves erectile functions in diabetic, hyperlipidemic rat models, as well as in neurogenic ED models. A recent meta-analysis indicated that stem cell therapy in neurogenic ED models recovers erectile function [5]. Periprostatic implantation with acellular scaffolds can promote cavernous nerve regeneration, but is less effective for smooth muscle cell recovery. ED models have provided evidence that homogenous clonal stem cells can overcome the inherent impediment of the heterogenous nature of isolated cells, providing optimism of the clinical value of stem cell therapy of ED. Successful ED therapy primarily relies on the improvement of functional and histological components. No direct evidence concerning the identification of stem cell differentiation has yet been described, suggesting the importance of paracrine action as a principle therapeutic mechanism in stem cell therapy of ED. Currently, two phase I-II stem cell clinical trials are recruiting patients with ED. One trial (NCT01089387) seeks to evaluate the efficacy of intracavernous injection of bone marrow stem cells in postradical prostatectomy patients. The other trial (NCT01601353) will evaluate the effect of intracavernous injection of adipose-derived stem cells in organic ED (vasculogenicand neural). Relative to other fields in urology, research on stem cell-related gene therapy for ED has been less robust. The few studies to date have involved stem cells
{"title":"Current status of stem cell therapy in urology.","authors":"Jae Heon Kim,&nbsp;Yun Seob Song","doi":"10.4111/kju.2015.56.6.409","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.409","url":null,"abstract":"Stem cells have the ability to propagate through self renewal and generate mature cells of multiple lineages through differentiation [1,2]. Explorations of the potential value of stem cell therapy in urology have included studies of bladder dysfunction, erectile dysfunction (ED), stress urinary incontinence (SUI), and prostate and bladder cancer. Only a few pilot human translational studies study of stress incontinence and diabetes induced ED have been reported. Recently, Alwaal et al. [3] introduced the current status of stem cell treatment in benign urological diseases including ED, Peyronie disease, infertility and SUI. \u0000 \u0000The prowess of stem cell therapy has been indicated in bladder dysfunction models including bladder outlet obstruction, chronic ischemia, diabetes, cryo-injury, pelvic nerve injury, and spinal cord injury (SCI). Except for cryo-injury and pelvic nerve injury, models have demonstrated overactive urodynamics, indicative of improved inter-contraction interval and maximal voiding pressure [1,2]. Underactivity models including cryo-injury and pelvic nerve injury models have demonstrated improvements of intravesical pressure. Marked smooth muscle differentiation has been reported in three studies. Concerning SCI-induced bladder dysfunction, a meta-analysis affirmed that stem cell-based cell therapyproduces partial bladder recovery including improvement of voiding pressure, inter-contraction interval, and residual urine [4]. \u0000 \u0000For ED, stem cell injection into the corpus cavernosum or periprostatic implantation improves erectile functions in diabetic, hyperlipidemic rat models, as well as in neurogenic ED models. A recent meta-analysis indicated that stem cell therapy in neurogenic ED models recovers erectile function [5]. Periprostatic implantation with acellular scaffolds can promote cavernous nerve regeneration, but is less effective for smooth muscle cell recovery. ED models have provided evidence that homogenous clonal stem cells can overcome the inherent impediment of the heterogenous nature of isolated cells, providing optimism of the clinical value of stem cell therapy of ED. \u0000 \u0000Successful ED therapy primarily relies on the improvement of functional and histological components. No direct evidence concerning the identification of stem cell differentiation has yet been described, suggesting the importance of paracrine action as a principle therapeutic mechanism in stem cell therapy of ED. Currently, two phase I-II stem cell clinical trials are recruiting patients with ED. One trial (NCT01089387) seeks to evaluate the efficacy of intracavernous injection of bone marrow stem cells in postradical prostatectomy patients. The other trial (NCT01601353) will evaluate the effect of intracavernous injection of adipose-derived stem cells in organic ED (vasculogenicand neural). \u0000 \u0000Relative to other fields in urology, research on stem cell-related gene therapy for ED has been less robust. The few studies to date have involved stem cells ","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"409-11"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.409","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33392995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Incidence of kidney, bladder, and prostate cancers in Korea: An update. 韩国肾癌、膀胱癌和前列腺癌的发病率:最新进展。
Pub Date : 2015-06-01 Epub Date: 2015-05-27 DOI: 10.4111/kju.2015.56.6.422
Wan Song, Hwang Gyun Jeon

The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future.

癌症的发病率正在急剧上升。癌症是导致死亡的主要原因,也是社会的一个重大负担。泌尿系肿瘤的发病率呈高于平均水平的上升趋势,将成为今后关注的重要问题。因此,全面准确地了解泌尿系肿瘤的发病率是至关重要的。在这项基于韩国国家癌症发病率数据库的研究中,分别检查了肾癌、膀胱癌和前列腺癌的年发病率、年龄标准化发病率、年百分比变化(APC)和年龄组分布。从1999年到2011年,各类型泌尿系统癌的总数为:肾癌(3.26万例,占25.5%)、膀胱癌(37950例,占29.7%)、前列腺癌(57332例,占44.8%)。前列腺癌的年龄标准化发病率显著增加,男性APC为12.3%。肾癌逐渐增加,男女APC均为6.0%,并在2008年后成为第二常见的泌尿系统癌症。膀胱癌无明显变化,男女APC均为-0.2%,自2007年以来略有下降。肾癌的年龄分布在50 ~ 54岁和65 ~ 69岁有两个高峰。膀胱癌和前列腺癌主要发生在70至74岁年龄组。肾癌的男女比例为2.5:1,膀胱癌的男女比例为5.6:1。我们总结了肾癌、膀胱癌和前列腺癌的发病率趋势,并为今后这些癌症的筛查和治疗提供了有用的信息。
{"title":"Incidence of kidney, bladder, and prostate cancers in Korea: An update.","authors":"Wan Song,&nbsp;Hwang Gyun Jeon","doi":"10.4111/kju.2015.56.6.422","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.422","url":null,"abstract":"<p><p>The incidence of cancer is sharply increasing. Cancer is a leading cause of death as well as a significant burden on society. The incidence of urological cancer has shown a higher than average increase and will become an important concern in the future. Therefore, an overall and accurate understanding of the incidence of urological cancer is essential. In this study, which was based on the Korea National Cancer Incidence Database, annual incident cases, age-standardized incidence rates, annual percentage change (APC), and distribution by age group were examined in kidney, bladder, and prostate cancers, respectively. From 1999 to 2011, the total number of each type of urological cancer was as follows: kidney cancer (32,600 cases, 25.5%), bladder cancer (37,950 cases, 29.7%), and prostate cancer (57,332 cases, 44.8%). The age-standardized incidence rates of prostate cancer showed a significant increase with an APC of 12.3% in males. Kidney cancer gradually increased with an APC of 6.0% for both sexes and became the second most frequent urological cancer after 2008. Bladder cancer showed no significant change with an APC of -0.2% for both sexes and has decreased slightly since 2007. The distribution of kidney cancer according to age showed two peaks in the 50- to 54-year-old and 65- to 69-year-old age groups. Bladder and prostate cancers occurred mostly in the 70- to 74-year-old age group. The proportions of male to female were 2.5:1 in kidney cancer and 5.6:1 in bladder cancer. We have summarized the incidence trends of kidney, bladder, and prostate cancers and have provided useful information for screening and management of these cancers in the future. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"422-8"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.422","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 36
Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy. 静脉注射头孢曲松和氟喹诺酮预防抗生素可减少经直肠超声引导前列腺活检后的感染并发症。
Pub Date : 2015-06-01 Epub Date: 2015-06-02 DOI: 10.4111/kju.2015.56.6.466
Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Myung-Soo Choo, Hanjong Ahn, Tai Young Ahn, Choung-Soo Kim

Purpose: To assess the rates of infectious complications before and after the change of prophylactic antibiotic regimens in prostate needle biopsy.

Materials and methods: The records of 5,577 patients who underwent prostate needle biopsy at Asan Medical Center between August 2005 and July 2012 were retrospectively reviewed. Group 1 (n=1,743) included patients treated between 2005 and 2009 with fluoroquinolone for 3 days, group 2 (n=2,723) included those treated between 2009 and 2012 with ceftriaxone once before the biopsy and fluoroquinolone before biopsy and continue therapy for 3 days, and group 3 (n=1,111) received the same treatment for more than 7 days after the biopsy. Univariable and multivariable logistic regression models addressed risk factors associated with infectious complication after prostate needle biopsy.

Results: Infectious complication after prostate needle biopsy developed in 18 (group 1), seven (group 2), and two patients (group 3) (p=0.001). In group 1, seven patients with infectious complication had positive blood cultures and harbored fluoroquinolone-resistant Escherichia coli, four had ceftriaxone susceptible isolates, and three had extended spectrum beta-lactamase-positive E. coli. Two patients in group 1 required intensive care because of septic shock. In multivariable analysis, the patients with combination of fluoroquinolone and ceftriaxone had significantly lower infectious complication rate than the fluoroquinolon alone (p=0.003).

Conclusions: Antibiotic prophylaxis with ceftriaxone and fluoroquinolone before prostate needle biopsy decreased the risk of potentially serious infectious complications.

目的:评价前列腺穿刺活检预防性抗生素方案改变前后感染并发症的发生率。材料与方法:回顾性分析2005年8月~ 2012年7月峨山医院行前列腺穿刺活检的5577例患者的资料。组1 (n= 1743)包括2005年至2009年期间使用氟喹诺酮治疗3天的患者,组2 (n= 2723)包括2009年至2012年期间在活检前使用头孢曲松1次,活检前使用氟喹诺酮并继续治疗3天的患者,组3 (n= 1111)在活检后使用相同治疗7天以上的患者。单变量和多变量logistic回归模型分析了前列腺穿刺活检后感染并发症的相关危险因素。结果:前列腺穿刺活检后出现感染性并发症18例(1组),7例(2组),2例(3组)(p=0.001)。1组7例感染并发症患者血培养阳性,含氟喹诺酮类耐药大肠杆菌,4例头孢曲松敏感,3例广谱β -内酰胺酶阳性大肠杆菌。1组2例患者因感染性休克需要重症监护。在多变量分析中,氟喹诺酮与头孢曲松合用患者感染并发症发生率明显低于氟喹诺酮单用患者(p=0.003)。结论:前列腺穿刺活检前使用头孢曲松和氟喹诺酮预防抗生素可降低潜在严重感染并发症的风险。
{"title":"Antibiotic prophylaxis with intravenous ceftriaxone and fluoroquinolone reduces infectious complications after transrectal ultrasound-guided prostatic biopsy.","authors":"Chunwoo Lee,&nbsp;Dalsan You,&nbsp;In Gab Jeong,&nbsp;Jun Hyuk Hong,&nbsp;Myung-Soo Choo,&nbsp;Hanjong Ahn,&nbsp;Tai Young Ahn,&nbsp;Choung-Soo Kim","doi":"10.4111/kju.2015.56.6.466","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.466","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the rates of infectious complications before and after the change of prophylactic antibiotic regimens in prostate needle biopsy.</p><p><strong>Materials and methods: </strong>The records of 5,577 patients who underwent prostate needle biopsy at Asan Medical Center between August 2005 and July 2012 were retrospectively reviewed. Group 1 (n=1,743) included patients treated between 2005 and 2009 with fluoroquinolone for 3 days, group 2 (n=2,723) included those treated between 2009 and 2012 with ceftriaxone once before the biopsy and fluoroquinolone before biopsy and continue therapy for 3 days, and group 3 (n=1,111) received the same treatment for more than 7 days after the biopsy. Univariable and multivariable logistic regression models addressed risk factors associated with infectious complication after prostate needle biopsy.</p><p><strong>Results: </strong>Infectious complication after prostate needle biopsy developed in 18 (group 1), seven (group 2), and two patients (group 3) (p=0.001). In group 1, seven patients with infectious complication had positive blood cultures and harbored fluoroquinolone-resistant Escherichia coli, four had ceftriaxone susceptible isolates, and three had extended spectrum beta-lactamase-positive E. coli. Two patients in group 1 required intensive care because of septic shock. In multivariable analysis, the patients with combination of fluoroquinolone and ceftriaxone had significantly lower infectious complication rate than the fluoroquinolon alone (p=0.003).</p><p><strong>Conclusions: </strong>Antibiotic prophylaxis with ceftriaxone and fluoroquinolone before prostate needle biopsy decreased the risk of potentially serious infectious complications.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"466-72"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.466","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33271899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Intraureteral and intravenous indocyanine green to facilitate robotic partial nephroureterectomy in a patient with complete ureteral triplication. 输尿管完全三折患者输尿管内及静脉注射吲哚菁绿促进机器人部分肾输尿管切除术。
Pub Date : 2015-06-01 Epub Date: 2015-05-27 DOI: 10.4111/kju.2015.56.6.473
Matthew Lee, Ziho Lee, Daniel Eun

A patient with a complete right ureteral triplication presented with recurrent pyelonephritis and flank pain that was refractory to medical management. Evaluation showed that the atrophic upper-most renal moiety had been chronically obstructed and was associated with a dilated ureter. Intraureteral and intravenous indocyanine green (ICG) were used as real-time contrast agents intraoperatively to facilitate right robotic partial nephroureterectomy of the diseased system. Intraureteral ICG was used to accurately distinguish the pathologic ureter and associated renal pelvis from its normal counterparts. Intravenous ICG was used to assess perfusion in the right kidney and delineate the margins of diseased renal parenchyma.

一个完全右输尿管三岔的病人表现为复发性肾盂肾炎和侧腹疼痛,对医学治疗难治性。评估显示萎缩的最上层肾脏部分长期梗阻,并伴有输尿管扩张。术中采用静脉注射吲哚菁绿(ICG)作为实时造影剂,促进机器人对病变系统进行右侧肾输尿管部分切除术。输尿管内ICG用于准确区分病变输尿管及相关肾盂与正常输尿管。静脉ICG用于评估右肾的灌注,并描绘病变肾实质的边缘。
{"title":"Intraureteral and intravenous indocyanine green to facilitate robotic partial nephroureterectomy in a patient with complete ureteral triplication.","authors":"Matthew Lee,&nbsp;Ziho Lee,&nbsp;Daniel Eun","doi":"10.4111/kju.2015.56.6.473","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.473","url":null,"abstract":"<p><p>A patient with a complete right ureteral triplication presented with recurrent pyelonephritis and flank pain that was refractory to medical management. Evaluation showed that the atrophic upper-most renal moiety had been chronically obstructed and was associated with a dilated ureter. Intraureteral and intravenous indocyanine green (ICG) were used as real-time contrast agents intraoperatively to facilitate right robotic partial nephroureterectomy of the diseased system. Intraureteral ICG was used to accurately distinguish the pathologic ureter and associated renal pelvis from its normal counterparts. Intravenous ICG was used to assess perfusion in the right kidney and delineate the margins of diseased renal parenchyma. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"473-6"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33271900","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 13
Cell-based therapy for kidney disease. 肾脏疾病的细胞疗法。
Pub Date : 2015-06-01 Epub Date: 2015-05-27 DOI: 10.4111/kju.2015.56.6.412
Hyun Chul Chung, In Kap Ko, Anthony Atala, James J Yoo

The prevalence of renal disease continues to increase worldwide. When normal kidney is injured, the damaged renal tissue undergoes pathological and physiological events that lead to acute and chronic kidney diseases, which frequently progress to end stage renal failure. Current treatment of these renal pathologies includes dialysis, which is incapable of restoring full renal function. To address this issue, cell-based therapy has become a potential therapeutic option to treat renal pathologies. Recent development in cell therapy has demonstrated promising therapeutic outcomes, in terms of restoration of renal structure and function impaired by renal disease. This review focuses on the cell therapy approaches for the treatment of kidney diseases, including various cell sources used, as well recent advances made in preclinical and clinical studies.

肾脏疾病的流行在世界范围内持续增加。当正常肾脏受到损伤时,受损的肾组织发生病理和生理事件,导致急性和慢性肾脏疾病,并经常发展为终末期肾功能衰竭。目前治疗这些肾脏疾病包括透析,这是无法恢复完全肾功能。为了解决这个问题,基于细胞的治疗已经成为治疗肾脏疾病的潜在治疗选择。细胞疗法的最新发展表明,在肾脏疾病引起的肾脏结构和功能损伤的恢复方面,有希望的治疗结果。本文综述了肾脏疾病的细胞治疗方法,包括使用的各种细胞来源,以及临床前和临床研究的最新进展。
{"title":"Cell-based therapy for kidney disease.","authors":"Hyun Chul Chung,&nbsp;In Kap Ko,&nbsp;Anthony Atala,&nbsp;James J Yoo","doi":"10.4111/kju.2015.56.6.412","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.412","url":null,"abstract":"<p><p>The prevalence of renal disease continues to increase worldwide. When normal kidney is injured, the damaged renal tissue undergoes pathological and physiological events that lead to acute and chronic kidney diseases, which frequently progress to end stage renal failure. Current treatment of these renal pathologies includes dialysis, which is incapable of restoring full renal function. To address this issue, cell-based therapy has become a potential therapeutic option to treat renal pathologies. Recent development in cell therapy has demonstrated promising therapeutic outcomes, in terms of restoration of renal structure and function impaired by renal disease. This review focuses on the cell therapy approaches for the treatment of kidney diseases, including various cell sources used, as well recent advances made in preclinical and clinical studies. </p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"412-21"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.412","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study. 第二次经尿道膀胱切除术治疗T1级膀胱癌的临床意义:一项前瞻性研究的结果。
Pub Date : 2015-06-01 Epub Date: 2015-05-28 DOI: 10.4111/kju.2015.56.6.429
Ji Sung Shim, Hoon Choi, Tae Il Noh, Jong Hyun Tae, Sung Goo Yoon, Seok Ho Kang, Jae Hyun Bae, Hong Seok Park, Jae Young Park

Purpose: This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer.

Materials and methods: Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method.

Results: Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and ≥T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant.

Conclusions: Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.

目的:本研究旨在评估第二次经尿道膀胱肿瘤切除术(turt)对最初诊断为T1级膀胱癌的患者的价值。材料和方法:2009年8月至2013年1月,共有29例T1级膀胱癌患者前瞻性地接受了第二次TURBT手术。评估包括先前未检测到的残余肿瘤的存在,组织病理学分期或分级的变化以及肿瘤的位置。采用Kaplan-Meier法生成无复发和无进展生存曲线,比较有和无残留病变组的预后。结果:29例患者中,22例(75.9%)患者在第二次TURBT术后残留病变。分期:无肿瘤7例(24.1%);Ta, 5人(17.2%);T1, 6 (20.7%);6人(20.7%);Ta+Tis, 1 (3.4%);T1+Tis, 1 (3.4%);≥T2, 3(10.3%)。24例(82.7%)患者在初次TURBT后手术标本中包括肌层。在三例第二次TURBT后癌症被抢到pT2的患者中,最初的手术标本包含肌肉层。残留病变组3年无复发生存率和3年无进展生存率分别为50%和66.9%,而无残留病变组3年无复发生存率和3年无进展生存率分别为68.6%和68.6%。这一差异无统计学意义。结论:最初的TURBT似乎不足以控制T1级膀胱癌。因此,对于T1级膀胱癌患者,应推荐常规的第二次TURBT手术,以完成充分的肿瘤切除,并确定可能需要及时行膀胱切除术的患者。
{"title":"The clinical significance of a second transurethral resection for T1 high-grade bladder cancer: Results of a prospective study.","authors":"Ji Sung Shim,&nbsp;Hoon Choi,&nbsp;Tae Il Noh,&nbsp;Jong Hyun Tae,&nbsp;Sung Goo Yoon,&nbsp;Seok Ho Kang,&nbsp;Jae Hyun Bae,&nbsp;Hong Seok Park,&nbsp;Jae Young Park","doi":"10.4111/kju.2015.56.6.429","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.429","url":null,"abstract":"<p><strong>Purpose: </strong>This study was designed to estimate the value of a second transurethral resection of bladder tumor (TURBT) procedure in patients with initially diagnosed T1 high-grade bladder cancer.</p><p><strong>Materials and methods: </strong>Between August 2009 and January 2013, a total of 29 patients with T1 high-grade bladder cancer prospectively underwent a second TURBT procedure. Evaluation included the presence of previously undetected residual tumor, changes to histopathological staging or grading, and tumor location. Recurrence-free and progression-free survival curves were generated to compare the prognosis between the groups with and without residual lesions by use of the Kaplan-Meier method.</p><p><strong>Results: </strong>Of 29 patients, 22 patients (75.9%) had residual disease after the second TURBT. Staging was as follows: no tumor, 7 (24.1%); Ta, 5 (17.2%); T1, 6 (20.7%); Tis, 6 (20.7%); Ta+Tis, 1 (3.4%); T1+Tis, 1 (3.4%); and ≥T2, 3 (10.3%). The muscle layer was included in the surgical specimen after the initial TURBT in 24 patients (82.7%). In three patients whose cancer was upstaged to pT2 after the second TURBT, the initial surgical specimen contained the muscle layer. In the group with residual lesions, the 3-year recurrence-free survival and 3-year progression-free survival rates were 50% and 66.9%, respectively, whereas these rates were 68.6% and 68.6%, respectively, in the group without residual lesions. This difference was not statistically significant.</p><p><strong>Conclusions: </strong>Initial TURBT does not seem to be enough to control T1 high-grade bladder cancer. Therefore, a routine second TURBT procedure should be recommended in patients with T1 high-grade bladder cancer to accomplish adequate tumor resection and to identify patients who may need to undergo prompt cystectomy.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"429-34"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer. 非肿瘤前列腺组织的二维新生血管复杂性明显高于低危前列腺癌。
Pub Date : 2015-06-01 Epub Date: 2015-06-02 DOI: 10.4111/kju.2015.56.6.435
Gianluigi Taverna, Fabio Grizzi, Piergiuseppe Colombo, Mauro Seveso, Guido Giusti, Silvia Proietti, Girolamo Fiorini, Giovanni Lughezzani, Paolo Casale, Nicolò Buffi, Massimo Lazzari, Giorgio Guazzoni

Purpose: Prostate cancer is the most frequent cancer in men in Europe. A major focus in urology is the identification of new biomarkers with improved accuracy in patients with low-risk prostate cancer. Here, we evaluated two-dimensional neovascular complexity in prostate tumor and nontumor biopsy cores by use of a computer-aided image analysis system and assessed the correlations between the results and selected clinical and pathological parameters of prostate carcinoma.

Materials and methods: A total of 280 prostate biopsy sections from a homogeneous series of 70 patients with low-risk prostate cancer (Gleason score 3+3, prostate-specific antigen [PSA]<10 ng/mL, and clinical stage T1c) who underwent systematic biopsy sampling and subsequent radical prostatectomy were analyzed. For each biopsy, 2-µm sections were treated with CD34 antibodies and were digitized by using an image analysis system that automatically estimates the surface fractal dimension.

Results: Our results showed that biopsy sections without cancer were significantly more vascularized than were tumors. No correlations were found between the vascular surface fractal dimension and patient's age, PSA and free-to-total PSA ratios, pathological stage, Gleason score, tumor volume, vascular invasion, capsular penetration, surgical margins, and biochemical recurrence.

Conclusions: The value of angiogenesis in prostate cancer is still controversial. Our findings suggest that low-risk prostate cancer tissues are less vascularized than are nontumor tissues. Further studies are necessary to understand whether angiogenesis is a hallmark of intermediate- and high-risk prostate cancer.

目的:前列腺癌是欧洲男性中最常见的癌症。泌尿外科的一个主要焦点是识别新的生物标志物,以提高低风险前列腺癌患者的准确性。在这里,我们使用计算机辅助图像分析系统评估前列腺肿瘤和非肿瘤活检核心的二维新生血管复杂性,并评估结果与选定的前列腺癌临床和病理参数之间的相关性。材料和方法:来自70例低危前列腺癌(Gleason评分3+3,前列腺特异性抗原[PSA])患者的280张前列腺活检切片结果:我们的研究结果显示,无癌活检切片血管化程度明显高于肿瘤切片。血管表面分形维数与患者年龄、PSA和游离总PSA比值、病理分期、Gleason评分、肿瘤体积、血管侵犯、囊膜穿透、手术切缘、生化复发无相关性。结论:血管生成在前列腺癌中的价值尚存争议。我们的研究结果表明,低风险前列腺癌组织的血管化程度低于非肿瘤组织。需要进一步的研究来了解血管生成是否是中高危前列腺癌的标志。
{"title":"Two-dimensional neovascular complexity is significantly higher in nontumor prostate tissue than in low-risk prostate cancer.","authors":"Gianluigi Taverna,&nbsp;Fabio Grizzi,&nbsp;Piergiuseppe Colombo,&nbsp;Mauro Seveso,&nbsp;Guido Giusti,&nbsp;Silvia Proietti,&nbsp;Girolamo Fiorini,&nbsp;Giovanni Lughezzani,&nbsp;Paolo Casale,&nbsp;Nicolò Buffi,&nbsp;Massimo Lazzari,&nbsp;Giorgio Guazzoni","doi":"10.4111/kju.2015.56.6.435","DOIUrl":"https://doi.org/10.4111/kju.2015.56.6.435","url":null,"abstract":"<p><strong>Purpose: </strong>Prostate cancer is the most frequent cancer in men in Europe. A major focus in urology is the identification of new biomarkers with improved accuracy in patients with low-risk prostate cancer. Here, we evaluated two-dimensional neovascular complexity in prostate tumor and nontumor biopsy cores by use of a computer-aided image analysis system and assessed the correlations between the results and selected clinical and pathological parameters of prostate carcinoma.</p><p><strong>Materials and methods: </strong>A total of 280 prostate biopsy sections from a homogeneous series of 70 patients with low-risk prostate cancer (Gleason score 3+3, prostate-specific antigen [PSA]<10 ng/mL, and clinical stage T1c) who underwent systematic biopsy sampling and subsequent radical prostatectomy were analyzed. For each biopsy, 2-µm sections were treated with CD34 antibodies and were digitized by using an image analysis system that automatically estimates the surface fractal dimension.</p><p><strong>Results: </strong>Our results showed that biopsy sections without cancer were significantly more vascularized than were tumors. No correlations were found between the vascular surface fractal dimension and patient's age, PSA and free-to-total PSA ratios, pathological stage, Gleason score, tumor volume, vascular invasion, capsular penetration, surgical margins, and biochemical recurrence.</p><p><strong>Conclusions: </strong>The value of angiogenesis in prostate cancer is still controversial. Our findings suggest that low-risk prostate cancer tissues are less vascularized than are nontumor tissues. Further studies are necessary to understand whether angiogenesis is a hallmark of intermediate- and high-risk prostate cancer.</p>","PeriodicalId":17819,"journal":{"name":"Korean Journal of Urology","volume":"56 6","pages":"435-42"},"PeriodicalIF":0.0,"publicationDate":"2015-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4111/kju.2015.56.6.435","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33266745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
期刊
Korean Journal of Urology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1